Interferon Therapy

  • Stergios J. Moschos
  • John M. Kirkwood


Clin Oncol Metastatic Melanoma Interferon Therapy Hairy Cell Leukemia Interferon Alfa 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Isaacs A, Lindenmann J. Virus Interference, I: Interferon. Proc Royal Soc Lond 1957;147:258–67.CrossRefGoogle Scholar
  2. 2.
    Gresser I, Belardelli F. Endogenous type I interferons as a defense against tumors. Cytokine Growth Factor Rev 2002;13(2):111–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Dunn GP, Bruce AT, Sheehan KC, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005;6(7):722–9. Epub 2005 Jun 12.PubMedCrossRefGoogle Scholar
  4. 4.
    Taniguchi T. Construction and Identification of a Bacterial Plasmid Containing the Human Fibroblast Interferon Gene Sequences. Proc Japan Acad 1979;55B(464–9).Google Scholar
  5. 5.
    Kontsek P, Karayianni-Vasconcelos G, Kontsekova E. The human interferon system: characterization and classification after discovery of novel members. Acta Virol 2003;47(4):201–15.PubMedGoogle Scholar
  6. 6.
    Taniguchi T, Takaoka A. A weak signal for strong responses: interferon-alpha/beta revisited. Nat Rev Mol Cell Biol 2001;2(5):378–86.PubMedCrossRefGoogle Scholar
  7. 7.
    Gohda J, Matsumura T, Inoue J. Cutting edge: TNFR-associated factor (TRAF) 6 is essential for MyD88-dependent pathway but not toll/IL-1 receptor domain-containing adaptor-inducing IFN-beta (TRIF)-dependent pathway in TLR signaling. J Immunol 2004;173(5):2913–7.PubMedGoogle Scholar
  8. 8.
    Fitzgerald KA, McWhirter SM, Faia KL, et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 2003;4(5):491–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Takaoka A, Yanai H, Kondo S, et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 2005;434(7030):243–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Honda K, Yanai H, Negishi H, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005;434(7034):772–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Harada H, Fujita T, Miyamoto M, et al. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 1989;58(4):729–39.PubMedCrossRefGoogle Scholar
  12. 12.
    Sarkar SN, Peters KL, Elco CP, Sakamoto S, Pal S, Sen GC. Novel roles of TLR3 tyrosine phosphorylation and PI3 kinase in double-stranded RNA signaling. Nat Struct Mol Biol 2004;11(11):1060–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Siren J, Pirhonen J, Julkunen I, Matikainen S. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J Immunol 2005;174(4):1932–7.PubMedGoogle Scholar
  14. 14.
    Tissari J, Siren J, Meri S, Julkunen I, Matikainen S. IFN-alpha enhances TLR3-mediated antiviral cytokine expression in human endothelial and epithelial cells by up-regulating TLR3 expression. J Immunol 2005;174(7):4289–94.PubMedGoogle Scholar
  15. 15.
    Kamath AT, Sheasby CE, Tough DF. Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma. J Immunol 2005;174(2):767–76.PubMedGoogle Scholar
  16. 16.
    Gautier G, Humbert M, Deauvieau F, et al. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med 2005;201(9):1435–46.PubMedCrossRefGoogle Scholar
  17. 17.
    Price KL, Herlyn M, Dent CL, Gewert DR, Linge C. The prevalence of interferon-alpha transcription defects in malignant melanoma. Melanoma Res 2005;15(2):91–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999;284(5421):1835–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005;23:275–306.PubMedCrossRefGoogle Scholar
  20. 20.
    Zou W, Machelon V, Coulomb-L’Hermin A, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001;7(12):1339–46.PubMedCrossRefGoogle Scholar
  21. 21.
    Wei S, Kryczek I, Zou L, et al. Plasmacytoid Dendritic Cells Induce CD8+ Regulatory T Cells In Human Ovarian Carcinoma. Cancer Res 2005;65(12):5020–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Hishizawa M, Imada K, Kitawaki T, Ueda M, Kadowaki N, Uchiyama T. Depletion and impaired interferon-alpha-producing capacity of blood plasmacytoid dendritic cells in human T-cell leukaemia virus type I-infected individuals. Br J Haematol 2004;125(5):568–75.PubMedCrossRefGoogle Scholar
  23. 23.
    Vermi W, Bonecchi R, Facchetti F, et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 2003;200(2):255–68.PubMedCrossRefGoogle Scholar
  24. 24.
    Treilleux I, Blay JY, Bendriss-Vermare N, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004;10(22):7466–74.PubMedCrossRefGoogle Scholar
  25. 25.
    Ito K, Tanaka H, Ito T, et al. Initial expression of interferon alpha receptor 2 (IFNAR2) on CD34-positive cells and its down-regulation correlate with clinical response to interferon therapy in chronic myelogenous leukemia. Eur J Haematol 2004;73(3):191–205.PubMedCrossRefGoogle Scholar
  26. 26.
    Massirer KB, Hirata MH, Silva AE, Ferraz ML, Nguyen NY, Hirata RD. Interferon-alpha receptor 1 mRNA expression in peripheral blood mononuclear cells is associated with response to interferon-alpha therapy of patients with chronic hepatitis C. Braz J Med Biol Res 2004;37(5):643–7. Epub 2004 Apr 22.PubMedCrossRefGoogle Scholar
  27. 27.
    Ambrus JL, Sr., Dembinski W, Ambrus JL, Jr., et al. Free interferon-alpha/beta receptors in the circulation of patients with adenocarcinoma. Cancer 2003;98(12):2730–3.PubMedCrossRefGoogle Scholar
  28. 28.
    Leyva L, Fernandez O, Fedetz M, et al. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J Neuroimmunol 2005;163(1–2):165–71.PubMedCrossRefGoogle Scholar
  29. 29.
    Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998;67:227–64.PubMedCrossRefGoogle Scholar
  30. 30.
    Saleh AZ, Fang AT, Arch AE, Neupane D, El Fiky A, Krolewski JJ. Regulated proteolysis of the IFNaR2 subunit of the interferon-alpha receptor. Oncogene 2004;23(42):7076–86.PubMedCrossRefGoogle Scholar
  31. 31.
    Subramaniam PS, Johnson HM. The IFNAR1 subunit of the type I IFN receptor complex contains a functional nuclear localization sequence. FEBS Lett 2004;578(3):207–10.PubMedCrossRefGoogle Scholar
  32. 32.
    Shin-Ya M, Hirai H, Satoh E, et al. Intracellular interferon triggers Jak/Stat signaling cascade and induces p53-dependent antiviral protection. Biochem Biophys Res Commun 2005;329(3):1139–46.PubMedCrossRefGoogle Scholar
  33. 33.
    Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005;5(5):375–86.PubMedCrossRefGoogle Scholar
  34. 34.
    Balkwill F, Taylor-Papadimitriou J. Interferon affects both G1 and S+G2 in cells stimulated from quiescence to growth. Nature 1978;274(5673):798–800.PubMedCrossRefGoogle Scholar
  35. 35.
    Takaoka A, Hayakawa S, Yanai H, et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003;424(6948):516–23.PubMedCrossRefGoogle Scholar
  36. 36.
    Kumar R, Atlas I. Interferon alpha induces the expression of retinoblastoma gene product in human Burkitt lymphoma Daudi cells: role in growth regulation. Proc Natl Acad Sci U S A 1992;89(14):6599–603.PubMedCrossRefGoogle Scholar
  37. 37.
    Subramaniam PS, Cruz PE, Hobeika AC, Johnson HM. Type I interferon induction of the Cdk-inhibitor p21WAF1 is accompanied by ordered G1 arrest, differentiation and apoptosis of the Daudi B-cell line. Oncogene 1998;16(14):1885–90.PubMedCrossRefGoogle Scholar
  38. 38.
    Tiefenbrun N, Melamed D, Levy N, et al. Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest. Mol Cell Biol 1996;16(7):3934–44.PubMedGoogle Scholar
  39. 39.
    Dondi E, Roue G, Yuste VJ, Susin SA, Pellegrini S. A dual role of IFN-alpha in the balance between proliferation and death of human CD4+ T lymphocytes during primary response. J Immunol 2004;173(6):3740–7.PubMedGoogle Scholar
  40. 40.
    Ozaki T, Takahashi K, Kanasaki H, Iida K, Miyazaki K. Expression of the type I interferon receptor and the interferon-induced Mx protein in human endometrium during the menstrual cycle. Fertil Steril 2005;83(1):163–70.PubMedCrossRefGoogle Scholar
  41. 41.
    Thyrell L, Erickson S, Zhivotovsky B, et al. Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene 2002;21(8):1251–62.PubMedCrossRefGoogle Scholar
  42. 42.
    Chawla-Sarkar M, Lindner DJ, Liu YF, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003;8(3):237–49.PubMedCrossRefGoogle Scholar
  43. 43.
    Wandinger KP, Lunemann JD, Wengert O, et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003;361(9374):2036–43.PubMedCrossRefGoogle Scholar
  44. 44.
    Shen L, Evel-Kabler K, Strube R, Chen SY. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol 2004;22(12):1546–53. Epub 2004 Nov 21.PubMedCrossRefGoogle Scholar
  45. 45.
    Li Z, Metze D, Nashan D, et al. Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol 2004;123(4):737–45.PubMedCrossRefGoogle Scholar
  46. 46.
    Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, et al. The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha. Haematologica 2004;89(1):42–8.PubMedGoogle Scholar
  47. 47.
    Liu B, Mink S, Wong KA, et al. PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat Immunol 2004;5(9):891–8. Epub 2004 Aug 15.PubMedCrossRefGoogle Scholar
  48. 48.
    Lesinski GB, Anghelina M, Zimmerer J, et al. The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. J Clin Invest 2003;112(2):170–80.PubMedCrossRefGoogle Scholar
  49. 49.
    Lesinski GB, Kondadasula SV, Crespin T, et al. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy. J Natl Cancer Inst 2004;96(17):1331–42.PubMedCrossRefGoogle Scholar
  50. 50.
    Jackson DP, Watling D, Rogers NC, et al. The JAK/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human melanoma cell line. Melanoma Res 2003;13(3):219–29.PubMedCrossRefGoogle Scholar
  51. 51.
    Lesinski GB, Valentino D, Hade EM, et al. Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy. Cancer Immunol Immunother 2005;25:25.Google Scholar
  52. 52.
    Certa U, Wilhelm-Seiler M, Foser S, Broger C, Neeb M. Expression modes of interferon-alpha inducible genes in sensitive and resistant human melanoma cells stimulated with regular and pegylated interferon-alpha. Gene 2003;315:79–86.PubMedCrossRefGoogle Scholar
  53. 53.
    Wong LH, Krauer KG, Hatzinisiriou I, et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem 1997;272(45):28779–85.PubMedCrossRefGoogle Scholar
  54. 54.
    Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003;22(20):3138–51.PubMedCrossRefGoogle Scholar
  55. 55.
    Sakamoto E, Hato F, Kato T, et al. Type I and type II interferons delay human neutrophil apoptosis via activation of STAT3 and up-regulation of cellular inhibitor of apoptosis 2. J Leukoc Biol 2005;78(1):301–9. Epub 2005 Apr 21.PubMedCrossRefGoogle Scholar
  56. 56.
    Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 1999;189(3):521–30.PubMedCrossRefGoogle Scholar
  57. 57.
    Litinskiy MB, Nardelli B, Hilbert DM, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002;3(9):822–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Loza MJ, Perussia B. Differential regulation of NK cell proliferation by type I and type II IFN. Int Immunol 2004;16(1):23–32.PubMedCrossRefGoogle Scholar
  59. 59.
    Petricoin EF, 3rd, Ito S, Williams BL, et al. Antiproliferative action of interferon-alpha requires components of T-cell-receptor signalling. Nature 1997;390(6660):629–32.PubMedCrossRefGoogle Scholar
  60. 60.
    Dondi E, Rogge L, Lutfalla G, Uze G, Pellegrini S. Down-modulation of responses to type I IFN upon T cell activation. J Immunol 2003;170(2):749–56.PubMedGoogle Scholar
  61. 61.
    Imai K, Ng AK, Glassy MC, Ferrone S. Differential effect of interferon on the expression of tumor-associated antigens and histocompatibility antigens on human melanoma cells: relationship to susceptibility to immune lysis mediated by monoclonal antibodies. J Immunol 1981;127(2):505–9.PubMedGoogle Scholar
  62. 62.
    Wagner SN, Rebmann V, Willers CP, Grosse-Wilde H, Goos M. Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma. Lancet 2000;356(9225):220–1.PubMedCrossRefGoogle Scholar
  63. 63.
    Ortaldo JR, Mason A, Rehberg E, et al. Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells. J Biol Chem 1983;258(24):15011–5.PubMedGoogle Scholar
  64. 64.
    Biron CA, Sonnenfeld G, Welsh RM. Interferon induces natural killer cell blastogenesis in vivo. J Leukoc Biol 1984;35(1):31–7.PubMedGoogle Scholar
  65. 65.
    Carballido JA, Molto LM, Manzano L, Olivier C, Salmeron OJ, Alvarez de Mon M. Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder. Cancer 1993;72(5):1743–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Uchida A, Vanky F, Klein E. Natural cytotoxicity of human blood lymphocytes and monocytes and their cytotoxic factors: effect of interferon on target cell susceptibility. J Natl Cancer Inst 1985;75(5):849–57.PubMedGoogle Scholar
  67. 67.
    Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996;272(5270):1947–50.PubMedCrossRefGoogle Scholar
  68. 68.
    Palmer KJ, Harries M, Gore ME, Collins MK. Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC). Clin Exp Immunol 2000;119(3):412–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Steitz J, Bruck J, Lenz J, Knop J, Tuting T. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res 2001;61(24):8643–6.PubMedGoogle Scholar
  70. 70.
    Guillot B, Portales P, Thanh AD, et al. The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment. Br J Dermatol 2005;152(4):690–6.PubMedCrossRefGoogle Scholar
  71. 71.
    Miettinen M, Sareneva T, Julkunen I, Matikainen S. IFNs activate toll-like receptor gene expression in viral infections. Genes Immun 2001;2(6):349–55.PubMedCrossRefGoogle Scholar
  72. 72.
    Gabriele L, Borghi P, Rozera C, et al. IFN-alpha promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. Blood 2004;103(3):980–7. Epub 2003 Oct 2.PubMedCrossRefGoogle Scholar
  73. 73.
    Abuzahra F, Heise R, Joussen S, et al. Adjuvant interferon alfa treatment for patients with malignant melanoma stimulates transporter proteins associated with antigen processing and proteasome activator 28. Lancet Oncol 2004;5(4):250.PubMedCrossRefGoogle Scholar
  74. 74.
    Ito T, Amakawa R, Kaisho T, et al. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 2002;195(11):1507–12.PubMedCrossRefGoogle Scholar
  75. 75.
    Diebold SS, Montoya M, Unger H, et al. Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature 2003;424(6946):324–8. Epub 2003 Jun 22.PubMedCrossRefGoogle Scholar
  76. 76.
    Pollara G, Jones M, Handley ME, et al. Herpes simplex virus type-1-induced activation of myeloid dendritic cells: the roles of virus cell interaction and paracrine type I IFN secretion. J Immunol 2004;173(6):4108–19.PubMedGoogle Scholar
  77. 77.
    Montoya M, Schiavoni G, Mattei F, et al. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 2002;99(9):3263–71.PubMedCrossRefGoogle Scholar
  78. 78.
    Mattei F, Schiavoni G, Belardelli F, Tough DF. IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J Immunol 2001;167(3):1179–87.PubMedGoogle Scholar
  79. 79.
    Tourkova IL, Yurkovetsky ZR, Gambotto A, et al. Increased function and survival of IL-15-transduced human dendritic cells are mediated by up-regulation of IL-15Ralpha and Bcl-2. J Leukoc Biol 2002;72(5):1037–45.PubMedGoogle Scholar
  80. 80.
    Luft T, Pang KC, Thomas E, et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 1998;161(4):1947–53.PubMedGoogle Scholar
  81. 81.
    Radvanyi LG, Banerjee A, Weir M, Messner H. Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells. Scand J Immunol 1999;50(5):499–509.PubMedCrossRefGoogle Scholar
  82. 82.
    Carbonneil C, Saidi H, Donkova-Petrini V, Weiss L. Dendritic cells generated in the presence of interferon-alpha stimulate allogeneic CD4+ T-cell proliferation: modulation by autocrine IL-10, enhanced T-cell apoptosis and T regulatory type 1 cells. Int Immunol 2004;16(7):1037–52. Epub 2004 Jun 7.PubMedCrossRefGoogle Scholar
  83. 83.
    Krug A, Veeraswamy R, Pekosz A, et al. Interferon-producing cells fail to induce proliferation of naive T cells but can promote expansion and T helper 1 differentiation of antigen-experienced unpolarized T cells. J Exp Med 2003;197(7):899–906.PubMedCrossRefGoogle Scholar
  84. 84.
    Tosi D, Valenti R, Cova A, et al. Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens. J Immunol 2004;172(9):5363–70.PubMedGoogle Scholar
  85. 85.
    Brinkmann V, Geiger T, Alkan S, Heusser CH. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J Exp Med 1993;178(5):1655–63.PubMedCrossRefGoogle Scholar
  86. 86.
    Schandene L, Del Prete GF, Cogan E, et al. Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells. J Clin Invest 1996;97(2):309–15.PubMedCrossRefGoogle Scholar
  87. 87.
    Rogge L, Barberis-Maino L, Biffi M, et al. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med 1997;185(5):825–31.PubMedCrossRefGoogle Scholar
  88. 88.
    Okada H, Tsugawa T, Sato H, et al. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines. Cancer Res 2004;64(16):5830–8.PubMedCrossRefGoogle Scholar
  89. 89.
    Astsaturov I, Petrella T, Bagriacik EU, et al. Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines. Clin Cancer Res 2003;9(12):4347–55.PubMedGoogle Scholar
  90. 90.
    Foster GR, Masri SH, David R, et al. IFN-alpha subtypes differentially affect human T cell motility. J Immunol 2004;173(3):1663–70.PubMedGoogle Scholar
  91. 91.
    Gutzmer R, Lisewski M, Zwirner J, et al. Human monocyte-derived dendritic cells are chemoattracted to C3a after up-regulation of the C3a receptor with interferons. Immunology 2004;111(4):435–43.PubMedCrossRefGoogle Scholar
  92. 92.
    Stylianou E, Yndestad A, Sikkeland LI, et al. Effects of interferon-alpha on gene expression of chemokines and members of the tumour necrosis factor superfamily in HIV-infected patients. Clin Exp Immunol 2002;130(2):279–85.PubMedCrossRefGoogle Scholar
  93. 93.
    Parlato S, Santini SM, Lapenta C, et al. Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood 2001;98(10):3022–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Zella D, Barabitskaja O, Casareto L, et al. Recombinant IFN-alpha (2b) increases the expression of apoptosis receptor CD95 and chemokine receptors CCR1 and CCR3 in monocytoid cells. J Immunol 1999;163(6):3169–75.PubMedGoogle Scholar
  95. 95.
    Hokeness KL, Kuziel WA, Biron CA, Salazar-Mather TP. Monocyte chemoattractant protein-1 and CCR2 interactions are required for IFN-alpha/beta-induced inflammatory responses and antiviral defense in liver. J Immunol 2005;174(3):1549–56.PubMedGoogle Scholar
  96. 96.
    Wenzel J, Uerlich M, Haller O, Bieber T, Tueting T. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod. J Cutan Pathol 2005;32(4):257–62.PubMedCrossRefGoogle Scholar
  97. 97.
    Wenzel J, Worenkamper E, Freutel S, et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol 2005;205(4):435–42.PubMedCrossRefGoogle Scholar
  98. 98.
    Hakansson A, Gustafsson B, Krysander L, Hakansson L. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer 1996;74(5):670–6.PubMedGoogle Scholar
  99. 99.
    Moschos SJ, Edington HD, Rao UN, et al. High dose Interferon- 2b (HDI): Toxicity, response, and predicitve markers in a neoadjuvant trial for regional lymph node metastatic melanoma. 2005. Proc Am Soc Clin Oncol 2005;23(16S):714s.Google Scholar
  100. 100.
    Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity 2003;36(8):511–8.PubMedCrossRefGoogle Scholar
  101. 101.
    Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979;301(1):5–8.PubMedCrossRefGoogle Scholar
  102. 102.
    Bengtsson AA, Sturfelt G, Truedsson L, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9(9):664–71.PubMedCrossRefGoogle Scholar
  103. 103.
    Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005;23(4):741–50. Epub 2004 Dec 21.PubMedCrossRefGoogle Scholar
  104. 104.
    Tsoutsos D, Ioannovich J, Frangia K, et al. The prevalence and prognostic significance of autoantibodies detected in patients with high risk melanoma receiving adjuvant therapy with high-dose interferon (Abstr 7519). Proc Am Soc Clin Oncol 2005;25.Google Scholar
  105. 105.
    Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001;294(5546):1540–3.PubMedCrossRefGoogle Scholar
  106. 106.
    Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005;202(1):135–43.PubMedCrossRefGoogle Scholar
  107. 107.
    Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A 2005;102(9):3372–7. Epub 2005 Feb 22.PubMedCrossRefGoogle Scholar
  108. 108.
    Zang GQ, Xi M, Feng ML, Ji Y, Yu YS, Tang ZH. Curative effects of interferon-alpha and HLA-DRB1 -DQA1 and -DQB1 alleles in chronic viral hepatitis B. World J Gastroenterol 2004;10(14):2116–8.PubMedGoogle Scholar
  109. 109.
    Wergeland S, Beiske A, Nyland H, et al. IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis. Eur J Neurol 2005;12(3):171–5.PubMedCrossRefGoogle Scholar
  110. 110.
    Yee LJ, Perez KA, Tang J, van Leeuwen DJ, Kaslow RA. Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection. J Infect Dis 2003;187(8):1264–71. Epub 2003 Apr 2.PubMedCrossRefGoogle Scholar
  111. 111.
    Takahashi M, Okada J, Ito K, et al. Electrochemical DNA array for simultaneous genotyping of single-nucleotide polymorphisms associated with the therapeutic effect of interferon. Clin Chem 2004;50(3):658–61.PubMedCrossRefGoogle Scholar
  112. 112.
    Mazziotti G, Sorvillo F, Piscopo M, et al. Innate and Acquired Immune System in Patients Developing Interferon-alpha-Related Autoimmune Thyroiditis: A Prospective Study. J Clin Endocrinol Metab 2005;90(7):4138–44. Epub 2005 Apr 26.PubMedCrossRefGoogle Scholar
  113. 113.
    Gutterman JU, Blumenschein GR, Alexanian R, et al. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 1980;93(3):399–406.PubMedGoogle Scholar
  114. 114.
    Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002;20(17):3703–18.PubMedCrossRefGoogle Scholar
  115. 115.
    Moschos SJ, Kirkwood JM, Konstantinopoulos PA. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b. J Clin Oncol 2004;22(1):11–4. Epub 2003 Dec 9.PubMedCrossRefGoogle Scholar
  116. 116.
    Capuron L, Neurauter G, Musselman DL, et al. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry 2003;54(9):906–14.PubMedCrossRefGoogle Scholar
  117. 117.
    Schwartz AL, Thompson JA, Masood N. Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum 2002;29(7):E85–90.PubMedCrossRefGoogle Scholar
  118. 118.
    Kowdley KV. Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol 2005;39(1 Suppl):S3–8.PubMedCrossRefGoogle Scholar
  119. 119.
    Houglum JE. Interferon: mechanisms of action and clinical value. Clin Pharm 1983;2(1):20–8.PubMedGoogle Scholar
  120. 120.
    Kirkwood JM, Ernstoff MS, Davis CA, Reiss M, Ferraresi R, Rudnick SA. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med 1985;103(1):32–6.PubMedGoogle Scholar
  121. 121.
    Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 1984;310(1):15–8.PubMedCrossRefGoogle Scholar
  122. 122.
    Vedantham S, Gamliel H, Golomb HM. Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy. Cancer Res 1992;52(5):1056–66.PubMedGoogle Scholar
  123. 123.
    Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986;314(17):1065–9.PubMedCrossRefGoogle Scholar
  124. 124.
    Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists’ Collaborative Group. J Natl Cancer Inst 1997;89(21):1616–20.Google Scholar
  125. 125.
    Verma A, Platanias LC. Signaling via the interferon-alpha receptor in chronic myelogenous leukemia cells. Leuk Lymphoma 2002;43(4):703–9.PubMedCrossRefGoogle Scholar
  126. 126.
    de Castro FA, Palma PV, Morais FR, et al. Immunological effects of interferon-alpha on chronic myelogenous leukemia. Leuk Lymphoma 2003;44(12):2061–7.PubMedCrossRefGoogle Scholar
  127. 127.
    Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999;353(9146):14–7.Google Scholar
  128. 128.
    Atzpodien J, Kirchner H, Illiger HJ, et al. IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001;85(8):1130–6.PubMedCrossRefGoogle Scholar
  129. 129.
    Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17(9):2859–67.PubMedGoogle Scholar
  130. 130.
    Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345(23):1655–9.PubMedCrossRefGoogle Scholar
  131. 131.
    Aass N, De Mulder PH, Mickisch GH, et al. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol 2005;23(18):4172–8.PubMedCrossRefGoogle Scholar
  132. 132.
    Atzpodien J, Kirchner H, Jonas U, et al. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004;22(7):1188–94. Epub 2004 Feb 23.PubMedCrossRefGoogle Scholar
  133. 133.
    Groopman JE, Gottlieb MS, Goodman J, et al. Recombinant alpha-2 interferon therapy for Kaposi’s sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 1984;100(5):671–6.PubMedGoogle Scholar
  134. 134.
    Real FX, Oettgen HF, Krown SE. Kaposi’s sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol 1986;4(4):544–51.PubMedGoogle Scholar
  135. 135.
    Evans LM, Itri LM, Campion M, et al. Interferon-alpha 2a in the treatment of acquired immunodeficiency syndrome-related Kaposi’s sarcoma. J Immunother 1991;10(1):39–50.PubMedCrossRefGoogle Scholar
  136. 136.
    Krown SE, Gold JW, Niedzwiecki D, et al. Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990;112(11):812–21.PubMedGoogle Scholar
  137. 137.
    Eriksson B, Oberg K, Alm G, et al. Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon. Lancet 1986;2(8519):1307–9.PubMedCrossRefGoogle Scholar
  138. 138.
    Bajetta E, Zilembo N, Di Bartolomeo M, et al. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group. Cancer 1993;72(10):3099–105.PubMedCrossRefGoogle Scholar
  139. 139.
    Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999;131(3):174–81.PubMedGoogle Scholar
  140. 140.
    Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005;142(2):105–14.PubMedGoogle Scholar
  141. 141.
    Shin DM, Khuri FR, Murphy B, et al. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 2001;19(12):3010–7.PubMedGoogle Scholar
  142. 142.
    Shin DM, Glisson BS, Khuri FR, et al. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol 2002;20(2):364–70.PubMedCrossRefGoogle Scholar
  143. 143.
    Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14(1):7–17.PubMedGoogle Scholar
  144. 144.
    Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18(12):2444–58.PubMedGoogle Scholar
  145. 145.
    Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19(9):2370–80.PubMedGoogle Scholar
  146. 146.
    Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995;13(11):2776–83.PubMedGoogle Scholar
  147. 147.
    Cameron DA, Cornbleet MC, Mackie RM, et al. Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer 2001;84(9):1146–9.PubMedCrossRefGoogle Scholar
  148. 148.
    Pehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998;16(4):1425–9.PubMedGoogle Scholar
  149. 149.
    Grob JJ, Dreno B, de la Salmoniere P, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998;351(9120):1905–10.PubMedCrossRefGoogle Scholar
  150. 150.
    Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001;358(9285):866–9.PubMedCrossRefGoogle Scholar
  151. 151.
    Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study–United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004;22(1):53–61. Epub 2003 Dec 9.PubMedCrossRefGoogle Scholar
  152. 152.
    Kleeberg UR, Suciu S, Brocker EB, et al. Final results of the EORTC 18871/DKG 80–1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 2004;40(3):390–402.PubMedCrossRefGoogle Scholar
  153. 153.
    Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E, Borden E. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1996;14(10):2666–73.PubMedGoogle Scholar
  154. 154.
    Hillner BE, Kirkwood JM, Atkins MB, Johnson ER, Smith TJ. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol 1997;15(6):2351–8.PubMedGoogle Scholar
  155. 155.
    Livingston PO, Wong GY, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12(5):1036–44.PubMedGoogle Scholar
  156. 156.
    Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10(5):1670–7.PubMedCrossRefGoogle Scholar
  157. 157.
    Sonnenblick M, Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest 1991;99(3):557–61.PubMedGoogle Scholar
  158. 158.
    Bradley JD, Scott CB, Paris KJ, et al. A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93–04). Int J Radiat Oncol Biol Phys 2002;52(5):1173–9.PubMedCrossRefGoogle Scholar
  159. 159.
    Gyorki DE, Ainslie J, Joon ML, Henderson MA, Millward M, McArthur GA. Concurrent adjuvant radiotherapy and interferon-alpha2b for resected high risk stage III melanoma – a retrospective single centre study. Melanoma Res 2004;14(3):223–30.PubMedCrossRefGoogle Scholar
  160. 160.
    Perera F, Fisher B, Kocha W, Plewes E, Taylor M, Vincent M. A phase I pilot study of pelvic radiation and alpha-2A interferon in patients with locally advanced or recurrent rectal cancer. Int J Radiat Oncol Biol Phys 1997;37(2):297–303.PubMedCrossRefGoogle Scholar
  161. 161.
    Legha SS, Ring S, Eton O, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998;16(5):1752–9.PubMedGoogle Scholar
  162. 162.
    Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998;16(5):1743–51.PubMedGoogle Scholar
  163. 163.
    Atkins MB, Lee S, Flaherty EJ, Sosman JA, Sondak VK, Kirkwood JM. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial (abstract 2847). Proc Am Soc Clin Oncol 2003.Google Scholar
  164. 164.
    Fluck M, Kamanabrou D, Lippold A, Reitz M, Atzpodien J. Dose-dependent treatment benefit in high-risk melanoma patients receiving adjuvant high-dose interferon alfa-2b. Cancer Biother Radiopharm 2005;20(3):280–9.PubMedCrossRefGoogle Scholar
  165. 165.
    Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004;22(4):610–6. Epub 2004 Jan 15.PubMedCrossRefGoogle Scholar
  166. 166.
    Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18(16):2972–80.PubMedGoogle Scholar
  167. 167.
    Moschos SJ, Odoux C, Land SR, et al. Endostatin plus Interferon-a2b therapy in patients with metastatic melanoma: a novel anti-angiogenic and immumodulatory cancer treatment. submitted.Google Scholar
  168. 168.
    Kirkwood JM, Lee S, Land S, et al. E1696: Final analysis of the clinical and immunological results of a multicenter ECOG phase II trial of multi-epitope peptide vaccination for stage IV melanoma with MART-1 (27–35), gp100 (209–210M), and tyrosinase (368–376, 370D) (MGT) +/- IFNa2b and GM-CSF (abstr 7502). Proc Am Soc Clin Oncol, 2004.Google Scholar
  169. 169.
    Okada H, Tsugawa T, Sato H, et al. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines. Cancer Res 2004;64(16):5830–8.PubMedCrossRefGoogle Scholar
  170. 170.
    Arico E, Robertson K, Allen D, Ferrantini M, Belardelli F, Nash AA. Humoral immune response and protection from viral infection in mice vaccinated with inactivated MHV-68: effects of type I interferon. J Interferon Cytokine Res 2002;22(11):1081–8.PubMedCrossRefGoogle Scholar
  171. 171.
    Gehring S, Gregory SH, Kuzushita N, Wands JR. Type 1 interferon augments DNA-based vaccination against hepatitis C virus core protein. J Med Virol 2005;75(2):249–57.PubMedCrossRefGoogle Scholar
  172. 172.
    Astsaturov I, Petrella T, Bagriacik EU, et al. Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines. Clin Cancer Res 2003;9(12):4347–55.PubMedGoogle Scholar
  173. 173.
    Dippold WG, Dienes HP, Knuth A, Meyer zum Buschenfelde KH. Immunohistochemical localization of ganglioside GD3 in human malignant melanoma, epithelial tumors, and normal tissues. Cancer Res 1985;45(8):3699–705.PubMedGoogle Scholar
  174. 174.
    Caldwell S, Heitger A, Shen W, Liu Y, Taylor B, Ladisch S. Mechanisms of ganglioside inhibition of APC function. J Immunol 2003;171(4):1676–83.PubMedGoogle Scholar
  175. 175.
    Vadhan-Raj S, Cordon-Cardo C, Carswell E, et al. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol 1988;6(10):1636–48.PubMedGoogle Scholar
  176. 176.
    Kirkwood JM, Mascari RA, Edington HD, et al. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer 2000;88(12):2693–702.PubMedCrossRefGoogle Scholar
  177. 177.
    Lee FT, Rigopoulos A, Hall C, et al. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts. Cancer Res 2001;61(11):4474–82.PubMedGoogle Scholar
  178. 178.
    Scott AM, Lee FT, Hopkins W, et al. Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial. J Clin Oncol 2001;19(19):3976–87.PubMedGoogle Scholar
  179. 179.
    Qu XJ, Yang JL, Russell PJ, Goldstein D. Changes in epidermal growth factor receptor expression in human bladder cancer cell lines following interferon-alpha treatment. J Urol 2004;172(2):733–8.PubMedCrossRefGoogle Scholar
  180. 180.
    Budillon A, Tagliaferri P, Caraglia M, et al. Upregulation of epidermal growth factor receptor induced by alpha-interferon in human epidermoid cancer cells. Cancer Res 1991;51(4):1294–9.PubMedGoogle Scholar
  181. 181.
    Boccellino M, Giuberti G, Quagliuolo L, et al. Apoptosis induced by interferon-alpha and antagonized by EGF is regulated by caspase-3-mediated cleavage of gelsolin in human epidermoid cancer cells. J Cell Physiol 2004;201(1):71–83.PubMedCrossRefGoogle Scholar
  182. 182.
    Tagliaferri P, Caraglia M, Budillon A, et al. New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer. Cancer Immunol Immunother 2005;54(1):1–10.PubMedCrossRefGoogle Scholar
  183. 183.
    Brunet JF, Denizot F, Luciani MF, et al. A new member of the immunoglobulin superfamily–CTLA-4. Nature 1987;328(6127):267–70.PubMedCrossRefGoogle Scholar
  184. 184.
    Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3(7):611–8.PubMedCrossRefGoogle Scholar
  185. 185.
    Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100(14):8372–7. Epub 2003 Jun 25.PubMedCrossRefGoogle Scholar
  186. 186.
    Ubaldi V, Gatta L, Pace L, Doria G, Pioli C. CTLA-4 engagement inhibits Th2 but not Th1 cell polarisation. Clin Dev Immunol 2003;10(1):13–7.PubMedCrossRefGoogle Scholar
  187. 187.
    Reuben JM, Lee BN, Shen DY, et al. Therapy with human monoclonal anti-CTLA-4 antibody, CP-675,206, reduces regulatory T cells and IL-10 production in patients with advanced malignant melanoma (MM). 2005.Google Scholar
  188. 188.
    Boasso A, Herbeuval JP, Hardy AW, Winkler C, Shearer GM. Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells. Blood 2005;105(4):1574–81. Epub 2004 Oct 5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2007

Authors and Affiliations

  • Stergios J. Moschos
    • 1
  • John M. Kirkwood
    • 1
  1. 1.The University of Pittsburgh Cancer Institute Melanoma CenterHillman Cancer Center, UPCI Research PavilionPittsburgh

Personalised recommendations